Latest news
first news image
July 9, 2024   |   News
Antonin (Tony) de Fougerolles appointed as Chair
first news image
May 21, 2024   |   News
etherna and Hasselt University announce autoimmune mRNA therapeutics research collaboration
first news image
April 16, 2024   |   News
Shelly West joins etherna as Business Development Director US

February 13, 2024   |   News
Landmark peer-reviewed paper shows etherna LNP formulations for intramuscular injection combine the induction of strong immune responses with significantly reduced local reactogenicity and systemic distribution
December 12, 2023   |   News
Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology
October 17, 2023   |   News
mRNA/LNP technology platform company etherna names Bernard Sagaert as Chief Executive Officer and Marijn Dekkers as Chairman of the Board
June 8, 2023   |   News
Steffen Helmling joins etherna as Chief Business Officer
March 25, 2023   |   News
Visit of His Majesty the King of the Belgians Philippe and Her Majesty the Queen of the Belgians Mathilde to Afrigen Biologics
January 9, 2023   |   News
Foundational RNA and cLNP expert Antonin (Tony) de Fougerolles joins etherna as independent board member
November 10, 2022   |   Awards
mRNA specialist etherna has been selected as a candidate for the M&A Award Life Sciences 2022
August 23, 2022   |   Research
mRNA leading expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers investing in EUR 39M Series B2 financing of mRNA technology platform company eTheRNA
Partner with us

Driving discovery and solving challenges for our partners, enabling them to deliver cost-effective, differentiated, and efficacious RNA therapeutics.